Explore the Agenda
7:30 am Morning Check-in & Light Breakfast
8:20 am Chair’s Opening Remarks
The Radiopharmaceutical Renaissance: Landscape Analysis & Clinical Updates
8:30 am Radiopharmaceutical Recap: Landscape Updates, Major Milestones & Trends for the Year(s) Ahead
• Sharing how the radiopharmaceuticals field is rapidly advancing, with growing clinical data shaping our understanding of pharmacokinetics, efficacy, and safety
• Examining where we stand and where we are heading across the landscape of therapeutic and diagnostic platforms
• Exploring radiation dosimetry, regulatory considerations, and manufacturing—highlighting key learnings and emerging challenges
9:00 am Illuminating a Future Beyond VISION 6×6 to Optimize Fixed Dosing Schedule
• Understanding whether we can do better than the approved fixed dosing schedule of Lu177-PSMA-617 for mCPRC patients: 7.4 Gbq per cycle, 6-week time interval between each cycle, up to 6 cycles max
• Reviewing literature and early findings from the UCLA IITs FLEX MRT NCT06216249 and RE-LuPSMA NCT06288113
• Exploring future considerations for optimal dosing
9:30 am The State of Radiopharmaceuticals: Growth, Challenges & What’s Ahead
• Explore early benefits, challenges, and driving forces behind radiopharma; learn how the industry has evolved, including current challenges and strategies for optimizing research
• Understand how research infrastructure must scale to meet growing demand
• Gain insights into future trends and how the industry can prepare for the next 5 years of innovation
10:00 am Panel Discussion: Exploring How Real-World Evidence Can Impact Design of Future RLT Trials
• Using real-world clinical outcomes to provide insights into patient populations, treatment efficacy and long-term safety
• Enhancing trial design through optimal patient selection, dosing strategies and endpoints
• Guiding potential personalized treatment strategies
10:30 am Speed Networking & Refreshments
A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.
Moving Beyond PSMA: Unlocking Novel Radiopharmaceutical Targets to Address Unmet Medical Need
11:30 am New Targets & Chemical Approaches to Maximize the Therapeutic Index for Targeted Radiotherapies
• Addressing approaches to exploit tumor specific antigens for targeted radiotherapy
• Exploring new drug delivery mechanisms to increase tumor absorbed dose of radiopharmaceuticals while minimally altering pharmacokinetic profile
12:00 pm Peptide Radioligand Development via PepLib’s Advanced Peptide Discovery Platform
• Introduction to PepLib's advanced peptide discovery platform and peptide radioligand pipelines
• Case studies on our radioligand development targeting FAP, GPC3, and DLL3
• Presentation of human IIT test results demonstrating the potency of our peptide radioligands
12:30 pm Building a Transformative Actinium-225 Portfolio for Next-Generation Precision Oncology
• Targeting the untapped: validation of novel tumor-specific targets for Actinium-225 radiotherapeutics
• Bridging preclinical to clinical: translational studies to optimize efficacy and patient selection
• Addressing high unmet need: Leveraging alpha-emitters to overcome resistance mechanisms
1:00 pm Lunch Break & Networking
Mining for Gold: Uncovering Novel Radiopharmaceutical Targets for Blockbuster Drugs
2:00 pm [At-211] Parthanatine: Bringing Alphas to Tumor DNA Using a PARP-Targeted Therapeutic Radiopharmaceutical for Novel Indications
• Outlining At-211 labelled PARP-inhibitor analogs to target a binding site located on DNA
• Subcellar targeting to tumor DNA yield high potency alpha RPT
• Preclinical data support efficacy and tolerable toxicity in challenging disease such as neuroblastoma and ovarian cancer
2:30 pm Roundtables- Using Artificial Intelligence for In-Silico Radiopharmaceutical Drug Design to De-risk Your Molecule
• Exploring screening through in-silico models
• Understanding what data it can bring
• Maximizing understandings for novel radiopharmaceuticals
3:00 pm Addressing Unmet Medical Need Through Novel Radiopharmaceutical CLDN18.2
• Exploring development to address gastric cancer
• Preclinical radioimmunoconjugate data
3:30 pm Afternoon Break & Poster Session
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of radiopharmaceutical
experts eager to hear the latest drug delivery innovations, you will have the opportunity to display a poster presenting your own research. Don’t miss out on the chance to connect, learn, and present.
Navigating Current Radiopharmaceutical Supply, Production & Building Talent Across the Field
4:00 pm Supply Chain State of the Union: Understanding the Current Manufacturing Environment for Radiopharmaceuticals
• Discussing the need for in-house manufacturing and the current and future roles of CDMOs in the radiopharma supply chain
• Exploring funding trends for companies developing radiopharmaceuticals and CDMOs supporting this sector
• Outlining current isotope availability, identifying supply bottlenecks, and projecting future isotype availability
4:30 pm Advancing the Future of RPT: Reserved for ITM
5:00 pm Panel Discussion: Maximizing the Talent Pool for Radiopharmaceuticals to Accelerate Drug Development
• Discussing how to preserve, recruit and keep your talent
• Identifying key bottlenecks from CMC to clinical personnel
• Exploring how to encourage and nurture new talent in the field: including pharma and academic involvement